To the shareholders of NLS Pharmaceutics AG, Zurich, Switzerland Zurich, 1 December 2023 Invitation to the Extraordinary Shareholders' Meeting of NLS Pharmaceutics AG, Zurich, Switzerland Dear Shareholder, The board of d

To the shareholders of

NLS Pharmaceutics AG, Zurich, Switzerland

Zurich, 1 December 2023

Extraordinary Shareholders' Meeting of NLS Pharmaceutics

AG, Zurich, Switzerland

The board of directors of NLS Pharmaceutics AG

(the "Board of Directors"), with registered office at The Circle 6, 8058 Zurich, Switzerland (the "Company")

is pleased to invite you to the extraordinary shareholders' meeting of the Company. The shareholders' meeting will be held as follows:

The agenda item to be voted on, the voting instructions

and the appendices mentioned herein are provided below:

The agenda item and proposal of the Board of

Directors is as follows:

The Board of Directors proposes to

newly elect Claudio Bassetti and Florence Allouche as members of the Board of Directors for a term lasting until the next annual ordinary

shareholders' meeting. Short biographies of the proposed new board members are attached hereto as Appendix 1.

[voting instructions and appendices

Voting Instructions:

Please note the following instructions with respect

to the participation in the extraordinary shareholders' meeting:

Shareholders who are entered in the

shareholder register maintained by our transfer Agent, VStock Transfer, LLC as of November 23, 2023, 11:59 pm CET (recording date), are

entitled to participate personally or be represented as provided for herein in order to exercise their shareholder rights with respect

to this extraordinary shareholders' meeting.

During the period from November 24,

2023 until and including December 22, 2023, no entries of shares will be made in the shareholder register. Shareholders who sell part

or all of their shares before this extraordinary shareholders' meeting are no longer entitled to vote to that extent. They are asked to

return or to exchange their voting material.

Shareholders are kindly requested

to return to NLS Pharmaceutics Ltd., attn. Marianne Lambertson (Head Investors Relations & Corporate Communication) per postal mail

(The Circle 6, 8058 Zurich, Switzerland) or e-mail (ml@nls-pharma.com) the registration form ("Registration Form") attached

as Appendix 2 duly completed and signed latest until December 17, 2023 (received by 11:59pm CET).

In the event that you do not intend

to participate personally in this extraordinary shareholders' meeting, you may be represented by the independent proxy, KBT Treuhand AG

Z rich, Kreuzplatz 5, 8032 Zurich, Switzerland (represented by Sandro M ller) or a third party (who need not to be a shareholder).

The draft power of attorney (proxy card) ("Proxy Card") is attached as Appendix 3.

The independent proxy will be physically

present at this extraordinary shareholders' meeting to vote on behalf of the shareholders who issued instructions to him. If the independent

proxy cannot be present, the Board of Directors will appoint a new independent proxy. The powers of attorney granted to the independent

proxy will also be valid for any new independent proxy appointed by the Board of Directors. In order to authorize the independent proxy,

the shareholders may vote by returning the marked, signed and dated Proxy Card by e-mail or mail in line with the instructions given therein,

or by voting on the internet (go to http://www.vstocktransfer.com/proxy, click on Proxy Voter Login and log-on using the control number

provided in the Proxy Card). Voting instructions must be given no later than December 21, 2023 (received by 11:59pm EST).

If you opt to be represented by a

third party (who need not be a shareholder), the completed and wet ink signed Proxy Card should be sent directly to the address of your

designated representative. Such designated representative may only cast your vote by providing the original wet ink signed Proxy Card

at the extraordinary shareholders' meeting which explicitly names the third party as your designated representative.

With the representation by the independent

proxy or a third party, a shareholder has no additional right of physical attendance at the extraordinary shareholders' meeting.

On behalf of the Board of Directors of NLS Pharmaceutics

Appendix 1: Biographies;

Appendix 2: Registration Form; and

Appendix 3: Proxy Card.

Claudio L. A. Bassetti

Full Professor and Chair, Neurology Department Inselspital, University

Hospital 3010 Bern, Switzerland claudio.bassetti@insel.ch

Claudio Lino Alberto Bassetti was

born and raised in Ticino, is married and father of three boys. He speaks six languages and enjoys music, history and sports.

Bassetti received his MD degree from

the University of Basel in 1984. He trained in neurology in Bern and Lausanne and performed research fellowships in experimental neurophysiology

(Basel) and sleep (Ann Arbor, USA). In 2000 he was appointed professor of Neurology at the University of Zurich. In 2009 he founded the

Neurocenter of Southern Switzerland. Since 2012 he is full professor at the University of Bern and director of the Neurology Department

Bassetti has been working throughout

his career mainly as a general neurologist with a special interest in clinical skills teaching. Using human and animal approaches he pioneered

the studies between sleep, sleep disorders and stroke. He also made fundamental contributions to the etiology, pathophysiology and management

of human narcolepsy. He authored over 560 publications (H index 105) and 10 books.

He served as president of the European Neurological

Society, European Sleep Research Society and Swiss Neurological Society (SNS) and European Academy of Neurology (EAN). He has been the

founder president of the Swiss Federation of Clinical Neurosocieties (SFCNS). For 8 years he served as board member of the Swiss Academy

of Medical Sciences (SAMS).

He currently serves as vice-president

of the European Brain Council (EBC) and Dean of the Medical Faculty in Bern. He is honorary member of the SNS and EAN.

Florence Allouche Aknin

Florence is Pharmacist Doctor by training, and MBA from HEC Paris,

She began her career as biologist

at AP-HP (Greater Paris Hospitals), then she held several positions in the diagnostics industry.

She created and managed for 16 years, the Tech Transfer Office of AP-HP.

75 startups created.

Expert & mentor at the

main Paris's incubators, she represented French technology transfer at international level (AUTM, ASTP).

In 2016, Florence co-founded

and was CEO of SPARINGVISION, a genomic medicines clinical stage company, developing a vision saving treatments for retinitis pigmentosa.

SparingVision raised 130M several European and French grants, in phase I/II clinical trial.

Florence is Professor at Faculty

of Pharmacy - University Paris City, specialized in pharmaceutical innovation and entrepreneurship.

She is elected member of the French National Academy of Pharmacy.

Florence is President of MYRPHARM ADVISORS, a startup studio for startup

creation, tech transfer, business development, innovation management, funding, strategy, growth, and mentoring.

With AUDACIA and ALOE Private equity and Sorbonne University, Florence

is launching SORBONNE VENTURE a 100M new fund, university and hospital backed dedicated to Deeptech / HealthTech.

Member of the Scientific Advisory Board of Venture Center of Excellence

Prev. Member of the Watching Committee for the Big Investment Plan

under the authority of French

Prime Minister (SGPI)

First Prize Biotech at the European Startups Competition CATAPULT

Finalist of the Prix Galien International, New York (US) - Med'Startup,

Mercure Entrepreneurs Award - HEC Paris 2019

Women Trajectory's Award - HEC Paris 2018

Elected "Woman of the Year 2017" by the French financial

magazine "La Tribune"